Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
This article was originally published in RPM Report
Former FDA Deputy Commissioner suggest Vaccine-For-Children model for high value drug purchasing programs during Johns Hopkins drug pricing conference. Bundled payments in Part D is another option put on the table. Medicare head Cavanaugh explains why that option is much harder to accomplish.
You may also be interested in...
CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.
CMS is shaking things up in Medicare Part B with a proposed demonstration project to test alternative reimbursement models for prescription drugs. But in Part D, CMS is taking more of a wait-and-see approach – at least in the annual update to the rules for bids on offering the insurance benefit.
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.